No images? Click here Welcome to The Corner. In this issue, we discuss Open Markets’ proposal to ban mergers during the COVID-19 pandemic and how the ventilator shortage demonstrates how monopolists make us unsafe. To read previous editions of The Corner, click here. The Shortage of Ventilators Demonstrates How Concentration Makes Us Unsafe
The New York Times reported last week that a 2012 acquisition by multinational medical device manufacturer Covidien stopped the planned production of highly affordable ventilators that the government had sought to produce in case of a national emergency. The lack of ventilators might well cost the lives of Americans suffering from COVID-19. As the Times report made clear, this shortage appears to be the result of an anti-competitive acquisition. In 2008, Newport Medical Instruments, a small medical device company in California, was awarded a government contract to produce 40,000 ventilators. These ventilators were meant to provide a buffer to meet the demand from hospitals during a national emergency, such as a pandemic, when lifesaving ventilators are needed. By 2010, Newport had developed a highly capable ventilator and had managed to lower the per-unit price to $3,000. However, after Newport was acquired by Covidien for $100 million, Covidien canceled the government contract, and no ventilators were ever produced for the original government project. As the total number of confirmed U.S. cases from COVID-19 surpassed 200,000 this week, hospitals are increasingly in dire need of ventilators for infected patients. New York Gov. Andrew Cuomo said his state, the hardest hit by the outbreak, will need 30,000 ventilators. The United States, however, only has 12,700 ventilators in the Strategic National Stockpile. The government has even asked Ford and General Motors to produce ventilators to increase our national supply. The ventilator shortage means that medical professionals will have to make difficult decisions, rationing ventilators to infected patients. Many of those hospitalized might die - unnecessarily - as a consequence of these decisions. Public officials and rivals say that Covidien bought Newport to eliminate Newport as a competitor in the ventilator business. Covidien pulled out of the government contract in 2014, possibly because the deal was not profitable enough for the company and would reduce its profits for its existing ventilator products. Covidien’s purchase of Newport is an example of a literal “killer acquisition” - one that has life or death consequences for individual Americans and families. This acquisition should have been illegal under antitrust law, as the merger substantially lessened competition in the already highly concentrated ventilator industry. In recent years, many reformers have adopted a framework of analysis based on the idea that the political economy has been “financialized” by Wall Street, and that this process has shifted economic activity away from making things to making money. But as the Times article on ventilator production makes clear, there is a much more simple explanation. This is that the radical overthrow of anti-monopoly law a generation ago freed monopolists and mercantilists to consolidate power over entire realms of the political economy, and to use their power in ways that degrade and destroy entire systems of production on which we rely for many of our most vital goods and services. As we noted in the last newsletter, in many instances this has resulted in the destruction of the redundancy of production necessary to ensure the resiliency and stability of the industrial systems themselves. In other instances, it has resulted in the destruction of vital industrial arts and skills, of machines and assembly lines, and of systems of innovation necessary to produce face masks, antibiotics, ventilators, and other manufactured items that keep us healthy and safe. The Open Markets team has pioneered reporting and analysis of this process of destruction. An early example was the 2005 book End of the Line, with its close analysis of how Boeing was wielding power in ways that destroyed its own supply system. The Open Markets team developed this analysis further in the Harper’s article “Breaking the Chain” in 2006 and in the 2010 book Cornered: The New Monopoly Capitalism and the Economics of Destruction. Read more of our important and timely work on these issues here:
Open Markets Calls for Ban on Takeovers by Large Corporations and Funds for Duration of Crisis The Open Markets Institute last week called on Congress, the Trump administration, and federal and state law enforcement agencies to impose an immediate ban on all mergers and acquisitions by any corporation with more than $100 million in annual revenue and by any financial institution or equity fund with more than $100 million in capitalization. The ban should remain in place for the duration of the present crisis. These mergers should be prohibited because the Antitrust Division of the Department of Justice (DOJ), the Federal Trade Commission (FTC), and other law enforcement agencies are now unable to effectively evaluate mergers, given the semi-closure of government because of COVID-19. More fundamentally, the ban is necessary to prevent a wholesale concentration of additional power by corporations that already dominate or largely dominate their industries, especially in ways that may significantly worsen the crisis that now threatens America’s health, social, and economic systems. The history of the panic of 2008 and the subsequent Great Recession instructs us that such a massive, uncontrolled consolidation will result in the unnecessary firing of millions of employees, the unnecessary bankrupting of innumerable independent businesses, a dramatic slowing of innovation in vital industries such as pharmaceuticals, and a further concentration of power and control dangerous both to our democracy and our open commercial systems. Federal regulators can take up the review of larger mergers once the health crisis has passed, but they should presume that deals pursued by corporations with more than $100 million in annual revenue, and by financial institutions or equity funds with more than $100 million in capitalization, are anti-competitive unless proven otherwise. Meanwhile, Congress should also make any corporate bailouts conditional on recipients not buying their competitors. We believe these measures are also merited because of the role concentration has played in undermining our public health, industrial, and financial systems in ways that have dramatically contributed to the COVID-19 crisis. Among other things, we believe such a temporary ban on takeovers by larger corporations and investment funds will immediately help to protect American jobs, promote industrial resiliency, and protect democratic institutions. Our full proposal can be read here. 🔊 ANTI-MONOPOLY RISING:
📝 WHAT WE'VE BEEN UP TO:
We appreciate your readership. Please consider making a contribution to support the continued publication of this newsletter. 📈 VITAL STAT:$121 billionThe value of the recently approved mega-merger between manufacturing conglomerate UTC and the defense contractor Raytheon. 📚 WHAT WE'RE READING:
Open Markets Employment Opportunities You can find the full job listings here. 🔎 TIPS? COMMENTS? SUGGESTIONS? We would love to hear from you—just reply to this e-mail and drop us a line. Give us your feedback, alert us to competition policy news, or let us know your favorite story from this issue. |